HUMANITY IS STRUGGLING to contain two compounding crises: skyrocketing global temperatures and plummeting biodiversity. But people tend to tackle each problem on its own, for instance deploying green energies and carbon-eating machines, while roping off ecosystems to preserve them. But in a new report, 50 scientists from around the world argue that treating each crisis in isolation means missing out on two-fer solutions that resolve both. Humanity can’t solve one without also solving the other.
To most people, giraffes are merely adorable, long-necked animals that rank near the top of a zoo visit or a photo-safari bucket list. But to a cardiovascular physiologist, there’s even more to love. Giraffes, it turns out, have solved a problem that kills millions of people every year: high blood pressure. Their solutions, only partly understood by scientists so far, involve pressurized organs, altered heart rhythms, blood storage — and the biological equivalent of support stockings.
Researchers have demonstrated just how easy it is to trick the mind into remembering something that didn’t happen. They also used two very simple techniques to reverse those false memories, in a feat that paves the way for a deeper understanding of how memory works.
Although medical experts have suggested that the coronavirus is much deadlier for men, studies have found that the male population is far less likely to take measures that could significantly reduce their chances of infection. But if the prospect of death isn’t enough to scare men into wearing masks or practice social distancing, perhaps the threat of impotence will.
A preliminary study published this month in JAMA Psychiatry presents evidence that psilocybin, the psychedelic ingredient in Psilocybe cubensis, or so-called magic mushrooms, may be a useful treatment for depression when paired with psychotherapy.
The Food and Drug Administration on Saturday issued an emergency use authorization to Regeneron for its covid-19 monoclonal antibody cocktail, which is made up of the antibodies casirivimab and imdevimab, citing a reduction in hospitalizations and emergency room visits in patients in a clinical trial as well as a reduction in viral load.